STOCK TITAN
  1. Home
  2. Sec-filings
  3. INM
  4. [8-K] InMed Pharmaceuticals Inc. Reports Material Event

Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq confirmed that the company’s common shares closed at or above $1.00 per share for 10 consecutive business days from May 19, 2026 through June 2, 2026.

This closes a prior deficiency notice InMed received in March 2026 after its shares traded below $1.00 for 30 consecutive business days. The company remains listed on Nasdaq and has disclosed the update via an 8-K and accompanying press release.

Positive

  • Nasdaq compliance restored: InMed regained compliance with Nasdaq Listing Rule 5550(a)(2) after its shares closed at or above $1.00 for 10 consecutive business days, removing an active bid-price delisting risk.

Negative

  • None.

Insights

InMed removes a Nasdaq listing deficiency by restoring its share price above the $1.00 minimum.

InMed Pharmaceuticals previously faced a Nasdaq deficiency because its common shares traded below $1.00 for 30 consecutive business days. Nasdaq listing rules require a minimum bid price of $1.00 to remain on the Nasdaq Capital Market.

Nasdaq has now determined that InMed’s shares closed at or above $1.00 for 10 straight business days from May 19, 2026 to June 2, 2026. That restores compliance with Nasdaq Listing Rule 5550(a)(2) and formally closes the matter.

This development removes the immediate risk of delisting tied to bid price for now. Future impact depends on whether the company can sustain its share price and continue meeting all Nasdaq standards, as highlighted in its forward-looking statements and risk disclosures.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) threshold
Days above minimum bid 10 consecutive business days May 19, 2026 to June 2, 2026
Initial deficiency notification date March 27, 2026 Nasdaq notice for trading below $1.00 for 30 days
Non-compliance period length 30 consecutive trading days Shares below $1.00 prior to March 27, 2026 notice
Nasdaq rule cited Rule 5550(a)(2) Minimum bid price requirement for Nasdaq Capital Market
Nasdaq Listing Rule 5550(a)(2) regulatory
"it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement"
minimum bid price requirement regulatory
"the minimum bid price requirement for continued listing on Nasdaq"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market regulatory
"requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
forward-looking information regulatory
"This news release contains "forward-looking information" and "forward-looking statements""
Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.
CB1/CB2 receptors medical
"developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors"
CB1 and CB2 receptors are two types of proteins on cells that interact with cannabinoids, the chemicals produced by cannabis plants and similar molecules made by the body. Think of them as door locks that control signals for mood, appetite, pain and immune activity; drugs that open or block those locks can change symptoms and health outcomes, so they are important targets for therapeutics, regulatory decisions and commercial opportunity in biotech and pharmaceutical investing.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 2026-06-03 0001728328 InMed Pharmaceuticals Inc. 0001728328 2026-06-03 2026-06-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

INMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

British Columbia 001-39685 98-1428279
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

Suite 1445 – 885 West Georgia Street
 Vancouver, British Columbia, Canada V6C 3E8
 (Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (604) 669-7207

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbols   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously reported, InMed Pharmaceuticals Inc. (the "Company") received a written notice on March 27, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") during the February 11, 2026 to March 26, 2026 period.


On June 3, 2026, the Company received written notice from Nasdaq informing the Company that, for the 10 consecutive business days from May 19, 2026 through June 2, 2026, the closing bid price of the Company's common shares had been at or above $1.00 per share. Accordingly, the Company has regained compliance with the Bid Price Requirement and Nasdaq has advised the Company that this matter is now closed.

On June 4, 2026, the Company issued a press release announcing that it had regained compliance with the Bid Price Requirement. A copy of the press release is filed as Exhibit 99.1 to this Current Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.   Description
     
99.1   Press Release
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  INMED PHARMACEUTICALS INC.
   
Date: June 4, 2026 By: /s/ Eric A Adams
    Eric A Adams
    President & CEO

2

 
NASDAQ: INM
 
Suite 1445-885 West Georgia St.
Vancouver, BC, Canada V6C 3E8
Tel: +1.604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com

InMed Pharmaceuticals Regains Compliance with Nasdaq Continued
Listing Requirements

Vancouver, BC - June 4, 2026 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.

As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now determined that the closing bid price of the Company's common stock was at or above $1.00 per share for 10 consecutive business days from May 19, 2026 to June 2, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq has advised the Company that the matter has been closed.

About InMed Pharmaceuticals

InMed is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T:  +1.604.416.0999

E:  ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the Company's ability to maintain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq, in the future.

With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things: the ability to maintain the minimum bid price of the Company's common shares at or above $1.00 per share on a sustained basis; the continued listing of the Company's common shares on Nasdaq; the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing the Company's business is disclosed in its Annual Report on Form 10-K,  Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Source: View Original Filing on SEC EDGAR

FAQ

What did InMed Pharmaceuticals (INM) announce in this 8-K filing?

InMed announced it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq confirmed the company’s shares closed at or above $1.00 for 10 consecutive business days, closing a previous deficiency notice.

Why was InMed Pharmaceuticals (INM) previously non-compliant with Nasdaq rules?

InMed was notified on March 27, 2026 that its common shares failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. This triggered a deficiency under Nasdaq Listing Rule 5550(a)(2) for the Nasdaq Capital Market.

How did InMed Pharmaceuticals (INM) regain Nasdaq bid price compliance?

InMed regained compliance after Nasdaq determined its common shares had a closing bid price at or above $1.00 per share for 10 consecutive business days, from May 19, 2026 through June 2, 2026, satisfying the minimum bid price rule.

What Nasdaq rule is relevant to InMed Pharmaceuticals’ (INM) listing status?

The relevant standard is Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market. InMed has now met this requirement following a 10-day period above that threshold.

Does InMed Pharmaceuticals’ (INM) Nasdaq compliance update affect its current listing?

Yes. Nasdaq advised that InMed has regained compliance with the minimum bid price requirement and that the matter is closed. As a result, the company continues to be listed on the Nasdaq Capital Market under its existing trading symbol.

What business does InMed Pharmaceuticals (INM) focus on?

InMed is a pharmaceutical company developing proprietary small-molecule drug candidates targeting CB1/CB2 receptors. Its pipeline includes three programs focused on treating Alzheimer’s, ocular conditions, and dermatological indications, according to the company’s description in the disclosure.

Filing Exhibits & Attachments

6 documents

Press Releases

Other Documents